மருந்துகள் கட்டுப்படுத்தி ஜநரல் இந்தியா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மருந்துகள் கட்டுப்படுத்தி ஜநரல் இந்தியா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மருந்துகள் கட்டுப்படுத்தி ஜநரல் இந்தியா Today - Breaking & Trending Today

Covid-19: The daily dose (July 5, 2021) - The Hindu BusinessLine

Covid-19: The daily dose (July 5, 2021) - The Hindu BusinessLine
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.

Veena George , Kerala Health , Panacea Biotec , Drugs Controller General India , Kerala Health Minister Veena George , வீணா ஜார்ஜ் , கேரள ஆரோக்கியம் , சஞ்சீவி பயோடெக் , மருந்துகள் கட்டுப்படுத்தி ஜநரல் இந்தியா ,

Panacea Biotec receives licence to produce Sputnik V vaccine at Himachal Pradesh

Panacea Biotec receives licence to produce Sputnik V vaccine at Himachal Pradesh
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.

Himachal Pradesh , Narendra Modi , Rajesh Jain , Gamaleya Center , Central Drug Laboratory , Russian Direct Investment Fund , Panacea Biotec , Drugs Controller General India , Sputnik Light , Managing Director , Prime Minister Narendra Modi , இமாச்சல் பிரதேஷ் , நரேந்திர மோடி , ராஜேஷ் ஜெயின் , மைய மருந்து ஆய்வகம் , ரஷ்ய நேரடி முதலீடு நிதி , சஞ்சீவி பயோடெக் , மருந்துகள் கட்டுப்படுத்தி ஜநரல் இந்தியா , ஸ்பட்நிக் ஒளி , நிர்வகித்தல் இயக்குனர் , ப்ரைம் அமைச்சர் நரேந்திர மோடி ,

Beware! 2DG COVID medicine will not see the daylight before June

The generic drugmaker released a statement on social media saying the anti-COVID remedy oral drug 2DG has not yet been launched into the market. Here, we advise our readers to remain vigilant and refrain themselves from falling into the trap of black marketers who lure them by offering the 2DG drug in exchange for a hefty amount. We request you to share this article with your friends and relative so as to alert your surroundings. ....

New Delhi , Institute Of Nuclear Medicine , Drugs Controller General India , Nuclear Medicine , Allied Sciences , 2dg Covid Medicine , Dr Reddy 039s Laboratories , 2dg Covid Drug , Covid 19 , Covid Vaccine , புதியது டெல்ஹி , நிறுவனம் ஆஃப் அணு மருந்து , மருந்துகள் கட்டுப்படுத்தி ஜநரல் இந்தியா , அணு மருந்து , கூட்டணி அறிவியல் ,

Data Suggests Phase-3 Trials For Covid Drug 2-DG May Continue Till August

Data Suggests Phase-3 Trials For Covid Drug 2-DG May Continue Till August
Data Suggests Phase-3 Trials For Covid Drug 2-DG May Continue Till August
The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients.
2-DG has been studied in more than 200 clinical trials for the treatment of various cancers globally.
New Delhi:
With the government presenting DRDO-developed drug 2-DG as a potential game-changer in the fight against COVID-19, the clinical trial registry data suggests that the phase-3 trials for the medicine at over two dozen government and private hospitals and involving 220 patients may continue till August. ....

India General , Tamil Nadu , Harsh Vardhan , Patanjali Pallavi Thakur , Shivam Singh , Anurag Varshney , Indian Council Of Medical Research , Ministry Of Defence , Health Ministry , Indian Journal Of Medical Research , Technical Sciences , Patanjali Research Institute Acharya Balkrishna , Viney Jain Vishwa Bharti Institute , Institute Of Nuclear Medicine , Data Suggests , For Covid Drug , Continue Till August , Patanjali Research Institute , Acharya Balkrishna , Swami Narsingh Dev , Viney Jain , Jain Vishwa Bharti Institute , Rakesh Kumar Sharma , Saveetha Institute , National Academy , Medical Sciences ,

Phase-3 clinical trials for 2-DG may continue till Aug: Registry data

With the government presenting DRDO-developed drug 2-DG as a potential game-changer in the fight against COVID-19, the clinical trial registry data suggests that the phase-3 trials for the medicine at over two dozen government and private hospitals and involving 220 patients may continue till August.
The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients.
While 2-DG has been studied in more than 200 clinical trials for the treatment of various cancers globally, trials to use it as a COVID-19 drug are apparently being done in India only and incidentally, a strong case for its therapeutic use against the novel coronavirus was made in a study paper last year that had Patanjali Research Institute s Acharya Balkrishna as the lead author. ....

India General , Tamil Nadu , Harsh Vardhan , Patanjali Pallavi Thakur , Shivam Singh , Anurag Varshney , Indian Council Of Medical Research , Ministry Of Defence , Health Ministry , Indian Journal Of Medical Research , Technical Sciences , Patanjali Research Institute Acharya Balkrishna , Viney Jain Vishwa Bharti Institute , Institute Of Nuclear Medicine , Patanjali Research Institute , Acharya Balkrishna , Swami Narsingh Dev , Viney Jain , Jain Vishwa Bharti Institute , Rakesh Kumar Sharma , Saveetha Institute , National Academy , Medical Sciences , Indian Journal , Medical Research , Indian Council ,